OMEICOS Therapeutics GmbH
🇩🇪Germany
- Country
- 🇩🇪Germany
- Ownership
- Holding
- Established
- 2013-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.omeicos.com
OMT-28 in Patients With Primary Mitochondrial Disease (PMD) (PMD-OPTION)
- First Posted Date
- 2023-08-02
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Omeicos Therapeutics GmbH
- Target Recruit Count
- 32
- Registration Number
- NCT05972954
- Locations
- 🇮🇹
IRCCS Institute of Neurological Science of Bologna, University of Bologna, Department of Biomedical and Neuromotor Science (DIBINEM), Ospedale Bellaria Via Altura, 3, Bologna, Italy
🇳🇱Radboud University Nijmegen Medical Centre, Nijmegen, Gelderland, Netherlands
🇮🇹U.O.C. di Neurologia e Malattie Neuromuscolari, Messina, Italy
Study on OMT-28 in Maintenance of Sinus Rhythm in Patients With Persistent Atrial Fibrillation (AF)
- First Posted Date
- 2019-04-08
- Last Posted Date
- 2021-09-09
- Lead Sponsor
- Omeicos Therapeutics GmbH
- Target Recruit Count
- 136
- Registration Number
- NCT03906799
- Locations
- 🇺🇦
Site 106, Kiev, Ukraine
🇺🇦Site 101, Kiev, Ukraine
🇺🇦Site 109, Kiev, Ukraine
Safety and Pharmacokinetic Study of OMT-28 in Healthy Subjects
- First Posted Date
- 2017-03-13
- Last Posted Date
- 2018-09-28
- Lead Sponsor
- Omeicos Therapeutics GmbH
- Target Recruit Count
- 75
- Registration Number
- NCT03078738
- Locations
- 🇩🇪
CRS-Mönchengladbach, Monchengladbach, Germany
© Copyright 2025. All Rights Reserved by MedPath